Company intelligence / Profile preview
Ischemix, Inc.
Grafton, Massachusetts, United Statesischemix.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
CMX-2043, the company's lead compound for TBI, has demonstrated safety in over 400 patients in clinical trials with no reported serious adverse drug-related events. It has shown promising preclinical results in sensorimotor activity, cognition, memory, contusion volume, hyperactive behavior, and biochemical assays. The company received a $2.9 million award from the US Department of Defense to fund a Phase 1 study of CMX-2043 for TBI.[1][3]
- Therapeutic areas
- CardiovascularNeurologyNephrology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
US Department of DefenseUS Army Medical Research and Development Command (USAMRDC)Combat Casualty Care Research Program (CCCRP)Medical Technology Enterprise Consortium (MTEC)
Beyond the preview
Go deeper on Ischemix, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ischemix, Inc..